Publicaciones en las que colabora con Nerea Varo Cenarruzabeitia (23)

2022

  1. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    OncoImmunology, Vol. 11, Núm. 1

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

2019

  1. Distrofias musculares

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 405-410

2018

  1. Liquid Biopsy: From Basic Research to Clinical Practice

    Advances in Clinical Chemistry (Academic Press Inc.), pp. 73-119

2015

  1. Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study

    International Journal of Cardiology, Vol. 185, pp. 177-185

  2. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

    Liver International, Vol. 35, Núm. 5, pp. 1590-1596

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

2012

  1. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 32, Núm. 6, pp. 1477-1487

  2. The influence of obesity on the assessment of carotid intima-media thickness

    Journal of Clinical Ultrasound, Vol. 40, Núm. 8, pp. 479-485

2011

  1. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis

    Critical Care, Vol. 15, Núm. 2

2008

  1. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome

    American Journal of Physiology - Endocrinology and Metabolism, Vol. 294, Núm. 1

  2. Immunosuppression Routed Via the Kynurenine Pathway: A Biochemical and Pathophysiologic Approach

    Advances in Clinical Chemistry, Vol. 45, Núm. SUPPL.: COMPLETE, pp. 155-197

  3. Response to association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity [4]

    Hypertension

2007

  1. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?

    Cardiovascular Research, Vol. 75, Núm. 3, pp. 536-545

2006

  1. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis

    Journal of the American College of Cardiology, Vol. 47, Núm. 7, pp. 1369-1378

2005

  1. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?

    Journal of Hypertension, Vol. 23, Núm. 3, pp. 625-632

  2. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients

    Journal of Hypertension, Vol. 23, Núm. 12, pp. 2297-2304

2001

  1. Biochemical assessment of myocardial fibrosis in hypertensive heart disease

    Hypertension

  2. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients

    Circulation, Vol. 104, Núm. 3, pp. 286-291

2000

  1. Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats

    Hypertension, Vol. 35, Núm. 6, pp. 1197-1202